$0.12 Earnings Per Share Expected for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) This Quarter

Equities research analysts expect that Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Rating) will report $0.12 earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Amneal Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.13 and the lowest estimate coming in at $0.11. Amneal Pharmaceuticals reported earnings of $0.20 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 40%. The firm is expected to announce its next earnings report before the market opens on Monday, January 1st.

On average, analysts expect that Amneal Pharmaceuticals will report full year earnings of $0.84 per share for the current fiscal year, with EPS estimates ranging from $0.82 to $0.85. For the next year, analysts anticipate that the firm will post earnings of $0.96 per share, with EPS estimates ranging from $0.86 to $1.10. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Amneal Pharmaceuticals.

Separately, StockNews.com initiated coverage on shares of Amneal Pharmaceuticals in a report on Thursday, March 31st. They issued a “buy” rating on the stock.

Shares of NASDAQ AMRX traded down $0.22 during midday trading on Friday, reaching $4.12. The company’s stock had a trading volume of 694,356 shares, compared to its average volume of 812,702. The company has a quick ratio of 1.52, a current ratio of 2.24 and a debt-to-equity ratio of 7.41. Amneal Pharmaceuticals has a fifty-two week low of $3.86 and a fifty-two week high of $6.21. The company has a market capitalization of $1.24 billion, a PE ratio of 58.86, a price-to-earnings-growth ratio of 0.22 and a beta of 1.21.

About Amneal Pharmaceuticals (Get Rating)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Stories